Objective: To investigate the clinical course of hyperprolactinemia without demonstrable cause.
Design: Prospective study of all patients with idiopathic hyperprolactinemia first seen between 1974 and 1985.
Setting: Outpatient Department of University Hospital.
Patients: Fifty-nine patients followed for 6 to 190 months (median 78 months). Medical treatment given only in case of anovulatory infertility or hypogonadism.
Outcome Measures: Development of pituitary (micro)prolactinoma, prolactin (PRL) levels, and clinical signs of menstrual dysfunction.
Results: With exception of one woman in whom it probably had been missed by hypocycloidal tomography, no demonstrable prolactinoma developed. Prolactin levels rose in two patients, one using oral contraceptives and the other with prolactinoma. At the end of follow-up, 15 of 16 patients using a dopaminergic drug had a normal cycle; 13 had normal final PRL levels. From the 43 patients off medication, 28 (66%) had normal PRL levels and 23 (54%) had a normal cycle. There were no significant differences between women who had and had not been pregnant. Dopaminergic medication had no appreciable influence on the course of the disease.
Conclusion: In idiopathic hyperprolactinemia, progression to pituitary prolactinoma seldom, if ever, occurs. There is a high tendency to spontaneous cure, and pregnancy or medication have no apparent effect. Frequent pituitary imaging was found to be not necessary in our patient population. It may best be reserved for situations in which the PRL level in symptomatic hyperprolactinemia is inconsistent with pituitary imaging results.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0015-0282(16)55139-5 | DOI Listing |
Pituitary
December 2024
Dipartimento di Medicina Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction: Empty sella is characterized by a flattened profile of the pituitary gland that represents in most cases only a radiological incidental finding. When endocrine, ophthalmic, and neurological symptoms occur, this condition is described as empty sella syndrome.
Materials And Methods: We searched MEDLINE (PubMed database) with the data filter 2024-2009 using the keywords listed above.
Rev Assoc Med Bras (1992)
November 2024
University of Campinas, School of Medicine - Campinas (SP), Brazil.
Objective: The aim of this study was to assess obstetric and perinatal outcomes in women with hyperprolactinemia according to the type of treatment indicated, with cabergoline or bromocriptine.
Methods: A retrospective cohort study with 464 women diagnosed with hyperprolactinemia was undertaken at the endocrine gynecology outpatient clinic of a tertiary hospital from May 2002 to February 2022. All women diagnosed with hyperprolactinemia who were being treated with dopamine agonists (cabergoline or bromocriptine) and who became pregnant during the follow-up were included.
Arch Endocrinol Metab
October 2024
Divisão de Endocrinologia Hospital Universitário de Brasília BrasíliaDF Brasil Divisão de Endocrinologia, Hospital Universitário de Brasília, Brasília, DF, Brasil.
Objective: Determining the etiology of hyperprolactinemia is fundamental for selecting the most appropriate treatment strategy. The aim of this study was to evaluate the usefulness and accuracy of prolactin levels in predicting the etiology of nonphysiological hyperprolactinemia.
Subjects And Methods: In this retrospective study, we reviewed medical records of patients with nonphysiological hyperprolactinemia seen at two neuroendocrine reference centers located in Recife, Brazil, from January 2000 to December 2019.
Rev Endocr Metab Disord
December 2024
Clinic for Pituitary Disorders, Department of Medicine, Zealand University Hospital, Køge, Denmark.
The homeo-fit-prolactin hypothesis proposes a causal metabolic role for prolactin with hypoprolactinemia and hyperprolactinemia leading to adverse metabolic alterations. However, prolactin within the normal range and up to four times the upper reference limit may be a consequence of metabolic adaption and have a positive metabolic role similar to increased insulin in pre-diabetes. As a consequence, drugs that would increase prolactin levels within this threshold may hold promising effects, particularly for patients with type 2 diabetes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!